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Abstract: Metabolomics is a new analytical technique defined as the study of the complex 
system of metabolites that is capable of describing the biochemical phenotype of a 
biological system. In recent years the literature has shown an increasing interest in 
paediatric obesity and the onset of diabetes and the metabolic syndrome in adulthood. 
Some studies show that fetal malnutrition, both excessive and insufficient, may 
permanently alter the metabolic processes of the fetus and increase the risk of future 
chronic pathologies. At present then, attention is being focused mainly on the formulation 
of new hypotheses, by means of metabolomics, concerning the biological mechanisms to 
departure from fetal-neonatal life that may predispose to the development of these diseases. 
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1. Introduction 
Metabolomics has been defined as the quantitative measurement over time of the metabolic 
response of a living system to pathophysiological stimuli and/or genetic modifications [1]. This 
discipline, based on the use of mathematical and statistical methods to solve multivariate problems, is 
capable of describing the chemical profile of a biological system in terms of low-molecular-weight 
metabolites present in cells, tissues, organs and biological fluids. By means of a metabolic approach it 
is thus possible “in real time” to photograph influences on the organism such as biochemical 
perturbations caused by diseases, drugs and toxins, thus delineating the biochemical phenotype of a 
OPEN ACCESS
Molecules 2013, 18 11725 
 
biological system [2]. In the medical field, attention is focusing on the definition at the biochemical 
and molecular levels of the different pathophysiological states that characterize human beings in the 
period that goes from embryonic development to ageing and death. The goal of this characterization is 
to develop “customized” therapeutic approaches for each individual. At present, the literature is 
focusing on new hypotheses concerning the biological mechanisms that lead to infantile obesity and 
the onset of diabetes and the metabolic syndrome in adulthood [3]. Experimental studies show that 
fetal malnutrition, both excessive and insufficient, may permanently alter the metabolic processes of 
the fetus and increase the risk of future chronic diseases. In this field the metabolomic studies in the 
literature appear promising in that they provide a sharper and more complete picture of the 
biochemical and molecular state in the pre- and post-natal period. They may be capable of revealing 
which metabolic alterations induced in the fetal period can be addressed to avoid the onset of diseases 
in adulthood. 
2. How Big Is the Problem? 
Cardiovascular diseases are the most important causes of death in all the World; every year  
4.3 million people die of them in Europe and they account for 48% of all deaths (54% women and  
43% men). Obesity and diabetes are also among the most important risk factors for ischemic 
cardiopathy and it is estimated that approximately 48 million adults in the European Union suffer from 
diabetes. Also to be considered is the fact that both the pathologies are on the increase [4]. Infantile 
obesity is also on the rise constantly and in many European countries one child out of five suffers from 
obesity or is overweight. A cause for concern is represented by the persistence of infantile obesity into 
adulthood, with the consequent increase in health risks [5]. In recent years, the coming to the fore of 
genomics and proteomics in the field of metabolic diseases has shown that infantile obesity and adult 
metabolic syndromes are closely connected by both genetic and environmental factors. In the literature 
we find many works that associate genetic polymorphisms with metabolic diseases such as diabetes 
and obesity both in adults and children [6–8]. However, relatively little is known about the 
mechanisms by means of which most gene loci act. Also poorly understood are the mechanisms by 
means of which the environment and a diet rich in fats, together with a sedentary lifestyle, may 
increase the risk of developing metabolic diseases [9]. 
3. The Foetal Hypothesis: Everything Begins at the Beginning 
The first scholar who hypothesized the foetal origin of certain chronic diseases of the adult was 
Barker [10,11]. This author suggested that changes in the intrauterine and early postnatal  
metabolic-nutritional environment impact on the basic vital processes and increase the risk of 
developing long-term diseases. This phenomenon, known as “perinatal programming” refers to 
intrauterine or perinatal events in a critical period of development for different organs and tissues that 
may negatively influence their proper functioning, with the possibility of making an individual more 
susceptible to contracting certain diseases than other. Then, the intrauterine environment defines the 
epigenetic profile of newborns, with implications for the risk of developing diseases later in adult life. 
This means that the programming of cardiovascular risk and obesity in adulthood takes place starting 
from intrauterine life. Barker suggested that there was a relationship between low birth weight and the 
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increased risk of contracting cardiovascular diseases. This theory is now accepted by most members of 
the academic community, not lastly because after Barker several other studies have found an 
association between low birth weight and the risk of presenting a metabolic syndrome and type 2 
diabetes in adulthood. This theory postulates that the underfed foetus activates a series of adaptive 
mechanisms to increase the immediate possibility of survival such as the storing of glucose to ensure 
nutrients to the most vital organs, with a consequent reduction in insulin secretion that continues in 
postnatal life, thus increasing the risk of obesity in later life [12]. However, some researchers have 
found that not only low birth weight, but also high birth weight, as in the case of diabetic mothers, is 
followed by an increased risk of developing type 2 diabetes in adulthood [13]. Harder et al. performed 
a meta-analysis [14] on the relationship between low/high birth weight and the onset of type 2 
diabetes. Some of these studies provided estimates which were adjusted for gestational age. The 
authors found a nonlinear, U-shaped association between birth weight and type 2 diabetes which led to 
an augmented risk both for high birth weight (LGA)(OR = 1.27) and low birth weight (SGA) neonates 
with respect to their gestational ages. This emphasizes that high birth weight was found to be 
associated with increased risk of type 2 diabetes in later life to the same extent as low birth weight. 
4. SGA & LGA: Are They Different? 
Traditionally the definition of SGA is an infant that has a birth weight below the 10th centile for 
gestational age. It is known as the low birth weight is in itself closely related to infant morbidity and 
mortality. In addition to prematurity, intrauterine growth retardation (IUGR), is considered one of the 
most important causes of low birth weight [15]. According to the classification of the American 
College of Obstetricians and Gynaecologists, IUGR is defined as a fetus that does not reach its growth 
potential and is characterized at birth by a weight or a body mass index below normal for the number 
of gestational weeks [16]. It should be emphasized that not all SGA infants identified at birth are 
patients with IUGR, as well as may be infants with IUGR are not classified as SGA. Among the many 
causes of IUGR, there are universally recognized risk factors such as cigarette smoking, maternal 
malnutrition and vascular/placenta disease [17]. It’s instead defined LGA or macrosoma as a neonate 
with a birth weight above the 90th centile for gestational age. Among the major risk factors for 
macrosomia include: maternal diabetes, obesity and excessive nutrition/weight gain during  
pregnancy [18]. Therefore it can be affirm that the intrauterine environment is the main factor that 
affects the growth and fetal development [19]. In fact, fetal life is a period characterized by phases of 
rapid cell proliferation and differentiation during which a factor damaging to the environmental 
(epigenetic) may cause permanent effects such as structural and functional alterations of organs, a 
reduction in the number of cells and a different adjustment of the hormonal axes. However, it is 
interesting to note that there are significant analogies between neonates with growth retardation and 
those of high birth weight. Firstly, macrosomia in LGA is selective as is microsomia in SGA: what is 
striking is the subcutaneous fat, the liver and the spleen, while the brain is safeguarded. The cranial 
circumference is normal, but there is a clear disproportion between this and the abdominal 
circumference (inversely proportional depending on whether it is a case of SGA or LGA). Moreover, 
despite the different foetal nutrition that accompanies the two pathologies, in both cases we can find 
quite similar complications at birth. In the case of a foetus with intrauterine growth retardation we can 
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hypothesize that a reduced carbohydrate amount may cause a reduction in insulin secretion, while in 
the LGA foetus there will be too much insulin caused by the hyperglycaemic condition it  
undergoes [20]. In any case, at birth the LGA baby often undergoes hypoglycaemia caused by chronic 
foetal hyperglycaemia which continues even after birth. The same complication frequently affects 
SGA neonates who maintain their hypoglycaemic condition after birth. Several studies on animal 
models have confirmed that exposure to a hyper- and hypoglycaemic environment in the uterus leads 
to reduced carbohydrate tolerance at birth which continues into adulthood, independently of subjects’ 
genetic predisposition [21,22]. This underscores the importance of epigenetics over genetics in the role 
of maternal-placental-foetal transmission. It would thus appear that SGA and LGA neonates, despite 
the opposing metabolism that characterizes them during their foetal life, find at birth a common 
condition of reduced carbohydrate tolerance that tends to persist during growth and into adulthood, 
consequently exposing them to a higher risk of developing pathologies such as obesity and type 2 
diabetes (Figure 1).  
Figure 1. Metabolic state characterizing SGAs and LGAs from foetal life to birth. 
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Another important element in the pathogenesis of a metabolic syndrome appears also to be neonatal 
overfeeding: the results of some authors [23] indicate that overfeeding in the neonatal period may lead 
to a “malprogramming” of the neuroendocrine circuits of the mediobasal hypothalamus that control 
appetite, body weight and the metabolism. It is also true that at present the nutritional practice in 
nurseries and neonatal intensive care units is to quickly recover the birth weight of infants, with the 
result that both SGAs and LGAs are fed to this end. The same can be said in the case of those with 
hypoglycaemia at birth: they receive the same therapy based on glycaemia values. 
5. Metabolites and Metabolomics in SGA and LGA 
Also as concerns the single metabolites, there appear to be important analogies between SGAs and 
LGAs, first and foremost those of leptin. Leptin, a hormone produced by adipose tissue, acts at the 
level of the hypothalamus to limit appetite and lipogenesis. It is capable of activating the mammalian 
target of rapamycin (mTOR) kinase which by regulating cell growth is essential in mediating leptin 
action in the hypothalamic circuits involved in regulating the body energy balance. In the blood of 
obese individuals we find high levels of leptin not associated with a reduced food intake: in such cases 
we speak of “leptin resistance” [24]. This can be attributed to genetic causes (lack of the receptor, lack 
of transducers of the leptin signal), but in most cases the cause cannot be identified exactly. The same 
resistance phenomenon takes place in type-2 diabetics who, although they produce large amounts of 
insulin, are still hyperglycemic and thus insulin-resistant. Insulin and leptin resistance often go hand in 
hand and may coexist in the same patient. It must also be kept in mind that the placenta is capable of 
producing a significant leptin amount and also insulin treatment increase the production of leptin by 
the placenta and as a result fetal circulating leptin. Such phenomena may be important owing to their 
long-term consequences for intrauterine growth and future energy homeostasis. Chronic fetal 
hyperleptinemia and accelerated fetal growth accompanied by increased amounts of body fat are 
frequent findings in the offspring of diabetic or obese mothers [25]. It is interesting to note that even 
low-birth-weight neonates have been associated with increased leptin values in the first months of life [26]. 
A study conducted on IUGR rats has demonstrated that chronic placental ischemia results in numerous 
alterations of the fetal environment that contribute to the development of impaired glucose 
metabolism, insulin resistance and hyperleptinemia in young offspring [27]. Recently, thanks to new 
metabolomic analysis techniques, studies have been performed to provide a more global vision of the 
metabolic profiles that characterize SGAs (Table 1). Only preliminary NMR spectroscopy data from 
the study by Logan et al. [28] have shown promising results in neonates of diabetic mothers. In 
comparison to a small number of newborn healthy term control infants, the urinary metabolic profiles 
of infants of diabetic mothers appeared to differ (Table 1). However, another work has been published 
in which changes in the serum metabolome were assessed prospectively in children who later 
progressed to type 1 diabetes [29] were assessed. The authors demonstrate that the appearance of 
insulin and glutamic acid decarboxylase autoantibodies was preceded by diminished ketoleucine and 
elevated glutamic acid. Recently, the same authors performed a study on non-obese pre-diabetic mice 
which recapitulated the design of the human study and derived the metabolic states from longitudinal 
lipidomics data. They showed that metabolomics confirmed dysregulation of energy and the amino 
acid metabolism in the islets of high-risk mice: in particular several key metabolites of these pathways 
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were found to be upregulated, including glutamic and aspartic acids [30]. It is interesting to note that 
the metabolites in SGAs and in those of the children of diabetic mothers as well as in children who 
later developed diabetes are closely correlated and all belong to the same metabolic cycle involved in 
the tricarboxylic acid (TCA) cycle. It is known that insulin plays an important role in energy 
generation through oxidation of acetyl-CoA and by favoring the conversion of glucose into piruvate in 
the TCA cycle. Insulin resistance or glucose intolerances may therefore lead to altered TCA cycle 
intermediates [31]. Thus it is probable that both the SGAs and the children of diabetic mothers showed 
a similar metabolic pattern for the very reason that they were both in a condition of reduced sensitivity 
to insulin at birth. In any case, it will be necessary in the future to uphold these results with further 
studies so as to arrive at a broader picture from the metabolic viewpoint of the two pathologies and, 
with the help of metabolomics, to compare the metabolic phenotype of SGAs and LGAs. 
Table 1. Metabolomic studies that analyze the metabolic profiles of SGAs and LGAs.  
Author Population study Sample Metabolomic analysis Metabolites results 
van Vliet  
et al. 2013 [32] 
10 IUGR vs. 6  
control rabbit fetuses 
Brains LC-QTOF-MS 
Aspargine, ornithine,  
N-acetylaspartylglutamic acid,  
N-acetylaspartate and palmitoleic acid 
Lin et al.  
2012 [33] 
18 IUGR vs. 18  
control pig fetuses 
Umbilical 
vein plasma 
Q-TOF MS 
Pyroglutamic acid,  
carnitine and creatinine 
Favretto et al.  
2012 [34] 
22 IUGR vs. 21  
control human neonates 
Cord blood LC-HRMS 
Phenilalanine, tryptophan  
acid and glutamate 
Logan et al.  
2012 [28] 
18 IDM vs. 12 healthy  
term control infants 
Urine NMR 
Glucose, formate, fumarate, succinate 
and citrate 
Dessì et al.  
2011 [35] 
26 IUGR vs. 30  
control human neonates  
Urine NMR 
Myo-inositol, sarcosine,  
carnitine and creatinine 
Horgan et al.  
2011 [36] 
8 IUGR vs. 6  
control human neonates 
Venous  
cord plasma 
UPLC-MS 
Phenylacetylglutamine,  
carnitine, hydroxybutyrate 
Nissen et al.  
2011 [37] 
12 IUGR vs. 12  
control newborn piglets 
Plasma NMR 
Myo-inositol and  
D-chiro-inositol 
6. Conclusions 
Metabolomics can be considered a valid, noninvasive instrument in the study of the components 
produced by the metabolism even in fetal and neonatal life. The studies published to date represent a 
starting point of fundamental importance in assessing the metabolic correlations between SGAs and 
LGAs for the purpose of identifying the single metabolites that characterize them. Feeding, as well as 
therapy in cases of hypoglycemia, should be customized and adapted to individual needs for both 
SGAs and LGAs, keeping in mind their long-term consequences. Data in the most recent publications 
suggest that by means of metabolomics it will be possible in the immediate future to monitor such 
patients over time to prevent the onset of chronic diseases in adulthood. 
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